Product revenue | 23.67M |
Cost of product revenue | 18.95M |
Gross margin | 4.72M |
Operating expenses: | |
Research and development | 2.58M |
Selling, general and administrative | 8.02M |
Restructuring charge | 581.6K |
Total operating expenses from continuing operations | 11.18M |
Operating loss from continuing operations | -6.46M |
Change in fair value of subordinated convertible notes and warrant liabilities | |
Other (loss) income, net | -170.32K |
Interest income | 11.01K |
Interest expense | -605.59K |
Loss from continuing operations before discontinued operations | |
Gain on sale of discontinued operations, net | |
Income from discontinued operations, net | |
Net loss | |
Deemed dividend and accretion on Series C preferred stock | |
Dividend on Series C preferred stock | |
Net loss attributable to common stockholders | |
Net loss per weighted average share, basic and diluted: | |
From loss from continuing operations before discontinued operations attributable to common stockholders (in dollars per share) | |
From income from discontinued operations (in dollars per share) | |
From gain on sale of discontinued operations (in dollars per share) | |
Net loss attributable to common stockholders per weighted average share, basic and diluted (in dollars per share) | -0.37 |
Weighted average number of common shares, basic (in shares) | |
Weighted average number of common shares, diluted (in shares) |